Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.87
+0.61 (4.60%)
At close: May 4, 2026, 4:00 PM EDT
13.88
+0.01 (0.07%)
After-hours: May 4, 2026, 7:58 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 377 employees as of December 31, 2025. The number of employees decreased by 26 or -6.45% compared to the previous year.
Employees
377
Change (1Y)
-26
Growth (1Y)
-6.45%
Revenue / Employee
$179,499
Profits / Employee
-$1,094,679
Market Cap
1.64B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 377 | -26 | -6.45% |
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Agios Pharmaceuticals | 540 |
| Vir Biotechnology | 367 |
| Nuvation Bio | 298 |
| Innoviva | 159 |
| Monte Rosa Therapeutics | 150 |
| Nanobiotix | 103 |
| AtaiBeckley | 99 |
NTLA News
- 3 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 7 days ago - Intellia Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 7 days ago - Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test - Benzinga
- 7 days ago - Intellia Therapeutics Transcript: Study result - Transcripts
- 7 days ago - Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial - Reuters
- 7 days ago - Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial - CNBC
- 7 days ago - Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema - GlobeNewsWire